Director Montalbano buys 20,000 ABCL shares at $4.77; holdings rise to 241,000 shares amid 160.6% annual revenue growth and -$43.2M net loss.
Director John S. Montalbano purchased 20,000 shares of AbCellera Biologics Inc. at $4.77 on 2026-05-14, increasing his holdings from 221,000 to 241,000 shares. The transaction occurs with the stock trading at $4.06 (37.7% below its 52-week high of $6.52), though the 90-day change shows +28.1% appreciation. AbCellera reported latest-quarter revenue of $8.3M with annual revenue growth of +160.6%, but remains unprofitable with net income of -$43.2M over the most recent full fiscal year, creating a fundamental tension between growth trajectory and profitability. Montalbano's prior three measurable purchases at this ticker yielded mixed 90-day outcomes ranging from -9.8% to +6.1%, with outcomes distributed between net positive and net negative performance.